Log in
Enquire now
‌

US Patent 9102761 Compositions for treatment of cancer

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9102761
Date of Patent
August 11, 2015
Patent Application Number
14568569
Date Filed
December 12, 2014
Patent Citations Received
‌
US Patent 12128069 Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
0
0
0
‌
US Patent 12076375 Treating and preventing
0
‌
US Patent 11667691 Treatment of cancer using chimeric CD3 receptor proteins
0
‌
US Patent 11680103 Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
0
‌
US Patent 11747346 Biomarkers predictive of cytokine release syndrome
‌
US Patent 11759480 Compositions and methods for CAR T cell therapy
...
Patent Primary Examiner
‌
Michael Burkhart
Patent abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9102761 Compositions for treatment of cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.